home

A flop in PhIII, spurned by the FDA, but NICE recommends PTC’s Duchenne drug

Trendfiercebiotech2016-04-18 09:56 Read   59

PTC Therapeutics’ Duchenne muscular dystrophy drug Translarna (ataluren) failed a pivotal Phase III and recently was spurned by the FDA, which refused to even consider the biotech’s application after regulators concluded that the company couldn’t make a case on efficacy. 

Ex-BGI CEO’s startup hits $1B valuation in 6 months

Frontierfiercebiotech2016-04-18 09:48 Read   74

Jun Wang has moved quickly since stepping down as CEO of Chinese genomics giant BGI to set up an artificial intelligence-enabled health data mining venture, iCarbonX.

Euronext Welcomes Swiss Biotechnology Pioneer GeNeuro To Paris Market - Raises €33 Million, Market Capitalisation Totals €190

Frontiermondovisione2016-04-18 09:36 Read   56

Euronext today celebrated the listing of GeNeuro, a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis, in Compartment B of its regulated market in Paris.

Illumina Invests In New Venture Fund

R&Dbusinesswire2016-04-18 09:24 Read   87

Illumina, Inc. (NASDAQ: ILMN) today announced that it has committed to invest $100M in a new venture capital firm that is strategically aligned with Illumina’s vision to improve human health by unlocking the power of the genome.

Stallergenes Greer PLC: Daniel Smith Appointed Global Head of Information Technology

EVENTSbusinesswire2016-04-18 09:18 Read   78

Stallergenes Greer plc, a biopharmaceutical company specializing in treatments for respiratory allergies, today announced the appointment of Daniel Smith as Global Head of Information Technology.

Q1 '16: Venture cash is still pouring into U.S. biotechs

Trendfiercebiotech2016-04-18 09:13 Read   59

Even as share prices and biotech valuations wilted under the glare of a savage bear market during the first quarter of the year, venture capital groups showed no signs of slowing down from last year’s torrid pace.

Macrocure Announces Receipt of NASDAQ Minimum Bid Price Notification

EVENTSYAHOO2016-04-18 09:07 Read   53

Macrocure Ltd. (MCUR), a clinical-stage biotechnology company, today announced that on April 7, 2016, Macrocure received a notice from NASDAQ regarding its non-compliance with the $1 per share minimum bid price requirement stated in NASDAQ Listing Rule 5450(a)(1).

April 12, 2016 03:05 AM Eastern Daylight Time

Trendbusinesswire2016-04-18 08:56 Read   67

Symphogen, announced today dosing of the first patient in its Sym015 program.

China's tougher vaccine rules 'welcome', complex to implement: WHO

EVENTSreuters2016-04-15 17:38 Read   66

China's proposals to impose tougher rules over its vaccine market will help stamp out illegal behavior and strengthen oversight, but will be "complex" to implement, the World Health Organization (WHO) said in a statement on Friday.

DAA therapy for HCV aids in deactivation, delisting of transplant patients

Frontierhealio2016-04-15 17:32 Read   56

Nearly 20% of patients with hepatitis C virus who received direct-acting antiviral therapy while on a transplant waiting list improved enough to be delisted, according to data presented here.

Therapy focus – Private companies in the Alzheimer's spotlight

R&Depvantage2016-04-15 17:25 Read   66

Last week’s decision by AstraZeneca and Lilly to advance their BACE inhibitor into phase III studies gives the stock market a new late-stage, potentially disease-modifying Alzheimer’s programme on which to fixate alongside Lilly’s solanezumab and Biogen’s aducanumab.

With $40M Led by GV, Quartet Expands Tech for Mental Health Care

EVENTSxconomy2016-04-15 17:12 Read   69

Quartet Health, the data-focused New York company that is trying to connect what it calls behavioral and physical healthcare, has received a $40 million Series B round led by GV, the venture capital arm of Google’s parent company, Alphabet.